The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
May 27th 2024
A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
DocTalk Podcast: Canagliflozin's Approval and SGLT2 Inhibitors with Dr. Bakris
October 7th 2019George Bakris, MD, professor of medicine at University of Chicago Medicine and member of CREDENCE steering committee, discusses the recent approval of canagliflozin and what it means for diabetic patients and their physicians.
Phase 2 Bardoxolone Trial Shows Efficacy for Alport Syndrome- & ADPKD-Caused CKD
Positive data collected from 2 phase 2 trials evaluating bardoxolone methyl in patients with chronic kidney disease (CKD) caused by Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) have been reported.
End-Stage Renal Disease Elevates Risk of Macular Degeneration
Age-related macular degeneration (AMD) was 72% more likely to develop in end-stage renal disease patients than in control subjects and 74% more likely to develop in peritoneal dialysis patients than in hemodialysis patients.
People with Advanced Chronic Kidney Disease Need More Vitamin D
April 1st 2016Vitamin D has shown to play an important role in those with multiple sclerosis, chronic obstructive pulmonary disease (COPD), and even depression; now it looks like the same can be said about those with stage 3 or 4 chronic kidney disease (CKD).
There is no shortage of people in need of a kidney transplant but a considerable shortage in the number of organs available to these patients. Despite that health care professionals in nephrology are determined to provide their patients the highest quality of life possible in spite of these challenges.
Medical Ethics: Should Older Patients with Heart and Kidney Failure Be Left to Die?
Older patients with heart and kidney failure can be helped with cardiac resynchronization therapy, a new study finds. But implanting devices to treat them is expensive, invasive, and not a full cure for many patients. Maybe it's better to ask these patients if they wouldn't rather die, two physicians argue.
Finerenone vs. Eplerenone: Trial Shows Mixed Results
In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide. But it had other benefits.